XRN2

Across TCGA pan-cancer cohorts, XRN2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of XRN2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where XRN2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types XRN2 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

COAD, LSCC, and HNSC are the cancer types where XRN2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in XRN2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	All	+0.582	<.001	12	view →
LSCC	Female	II,III,IV	+0.427	<.001	9	view →
HNSC	Male	IV	+0.416	<.001	8	view →
LUAD	Male	III,IV	+0.339	<.001	8	view →
PDAC	Female	All	−0.151	.003	5	view →
OV	All	All	+0.304	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

XRN2–COAD

Open the COAD breakdown →